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The new two-component conformity index 
formula (TCCI) and dose-volume compari-
sons of the pituitary gland and tonsil cancer 
IMRT plans using a linear accelerator and 
helical Tomotherapy
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ABSTRACT: 
BACKGROUND/AIM: To examine the new dose-volume verifi cation tool, called the two-component 
conformity index formula (TCCI), for tumours of the pituitary gland and tonsil cancer IMRT plans using 
helical Tomotherapy and a linear accelerator.
MATERIAL AND METHODS: 10 medically inoperable patients – 5 with tumour of the pituitary gland 
and 5 tonsil cancers – were considered. Tomotherapy and Eclipse plans were compared by DVH analy-
sis and new TCCI analysis including: 1/ the physician’s intents for dose distribution in PRVs, 2/ more 
than one dose-volume constraint for dose distribution in PTV and healthy tissues, and 3/ separation 
between coverage and excess components.
RESULTS: DVH analysis shows differences for the PTV received doses close to the prescription dose 
(PD): 1/ in pituitary gland, Eclipse – 61% of PTV volume enclosed by PD and Tomotherapy – 50%, and 
2/ in tonsil cancer, Eclipse plans – 44% and Tomotherapy – 55%. These differences were clinically con-
fi rmed for tonsil cancer through TCCI analysis. Moreover, TCCI analysis shows better coverage of PTV 
volume through 90% and 95% isodose levels for Tomotherapy plans. Better high dose region reduc-
tion for brain stem and optic chiasm in pituitary gland and middle dose region reduction for parotids 
and spinal cord in tonsil and dose reduction in healthy tissues reported by TCCI analysis were observed 
for Tomotherapy plans.
CONCLUSIONS: The usefulness of the information provided means that TCCI could be used as a pri-
mary or alternative method of quick dose-volume verifi cation fi nally supported by advanced DVH 
analysis.
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INTRODUCTION
The main aims of current radiotherapy treat-
ment are to make the high dose volume con-
form to the planning target volume (PTV) and 
spare the organs at risk in close proximity [1–
3]. The very complex nature of plans derived 
by current radiotherapy techniques requires a 
lot of dose-volume-based parameters that have 
been used to evaluate external beam plans. 
Apart from the physical dose parameters (e.g. 
minimum, maximum, median, mean dose and 
their standard deviation for planning target 
volume (PTV) and planning risk volumes 
(PRVs)), equivalent uniform dose is used for 
evaluation of plans [4–10]. Moreover, several 
volume-based dosimetric indices called con-
formity indices (CI) were developed as an ad-
ditional tool to numerically quantify the dose 
distributions. CI can be generally defi ned as 
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an absolute value resulting from the relation-
ship between PTV and the volume delineated 
by an isodose. It can also be defi ned by the ra-
tio of an isodose to another isodose (prescrip-
tion isodose, reference isodose, minimum 
isodose, maximum isodose) [11]. The fi rst con-
formity index was proposed in 1993 by the Ra-
diation Therapy Oncology Group (RTOG) and 
described in Report 50 of the International 
Commission on Radiation Units and Measure-
ments (ICRU) [12, 13]. In the last few years, 
other authors have proposed their formula of 
the CI with various names [14–19].
However, the multiple indices proposed, 
as well as the diffi culty in interpreting them, 
raise a number of problems. The use of one nu-
merical value including coverage of PTV and 
excess volume of the high dose region is not a 
clear solution. Theoretically the same value of 
CI can be observed for two different clinical 
situations. Current ICRU recommendations 
suggest that four dose-volume constraints can 
be used for verifi cation of dose distribution in 
PTV [20]. In this way, only one isodose level 
according to the CI calculation formula pro-
vides an imprecise result of the PTV cover-
age by the high dose region. Moreover, fi nal 
values of current CI computations are more 
dependent on the excess than the coverage 
component. This dependence provides differ-
ent results of CI for treatment plans grouped 
by different volumes or regions of irradiation. 
The aforementioned shortcomings of the ex-
isting CI indices have resulted in its present 
status, being only an additional tool used for 
comparison of dose distribution between two 
plans performed for the same region of irra-
diation or the same technique. Moreover, ex-
isting CI indices are completely insuffi cient 
for scoring plans performed for different 
treatment volumes in the same regions (for 
example: large and small brain tumours) or 
techniques (for example: linear accelerator 
and Tomotherapy IMRT).
In this study a new idea of CI called the 
two-component conformity index formula 
(TCCI) is presented. The presented TCCI for-
mula includes: 1/ the physician’s intents for 
dose distribution in PRVs, 2/ more than one 
dose-volume constraint for dose distribution 
in PTV and healthy tissues, and 3/ separation 
between coverage and excess components.
Tomotherapy and linear accelerator IMRT 
plans of the pituitary gland and tonsil can-
cers were prepared and evaluated by the 
TCCI formula. Additionally, functionality of 
the TCCI computations are discussed in the 
light of selected CI formulas currently used 
for plan scoring. Moreover, complementary 
DVH analysis was performed in which curves 
and selected parameters of DVH obtained for 
Tomotherapy and accelerator plans were col-
lected and presented.
MATERIALS AND METHODS
Patients
Ten medically inoperable patients – fi ve with 
tumour of the pituitary gland and fi ve with 
oropharyngeal cancer (tonsil, T2N0M0) – pre-
viously treated with IMRT at the Greater Po-
land Cancer Centre between 2005 and 2006 
with radical intent were considered for this 
study. Simulation on the Acuity System (Var-
ian Corp.) and CT scans (Somatom Sensation 
Open, Siemens Corp.) registered by match 
point method with MR scans (Sigma Excite 
1.5T, GE Corp.) were performed for all pa-
tients. The slice thickness was 5 mm in tonsil 
cancer and 3 mm in pituitary gland tumour. 
Patients were positioned in a supine position 
with a thermoplastic mask (Sinmed Corp.) 
with 5 fi xation points for tonsil cancer and 3 
fi xation points for pituitary gland, respective-
ly. The masks were fi xed to the Posifi x® IMRT 
base-plate (Sinmed Corp.)
The dose prescription used for patients 
with tumour of the pituitary gland was 56 
Gy delivered in 28 fractions. In patients 
with tonsil cancer the following treatment 
volumes were delineated and dose prescrip-
tions were as follows: 1/ CTV1 defi ned as 
GTV with 5 mm margins received 70 Gy 
in 35 fractions, 2/ CTV2 – high-risk lymph 
node region (ipsilateral II, Ib lymph node 
regions according to 2003 delineation guide-
lines consensus [21]) received 60 Gy in 30 
fractions, and 3/ CTV3 defi ned as ipsilat-
eral (III-V) and contralateral lymph nodes 
(Ib-V) and retropharyngeal LN received 50 
Gy in 25 fractions. Similarly as in pituitary 
gland cases, to complicate the optimization 
process different dose prescription was se-
lected in a way that CTV2 were simulated to 
receive 70 Gy in 35 fractions.
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All contours were delineated on the Soma Vi-
sion station (Varian Corp.) by one physician and 
automatically sent to the Eclipse (Varian Corp) 
and the HiArt Tomotherapy Planning Station. 
The PTVs were defi ned as CTV with 3 mm mar-
gins except the fi rst phase of tonsil cancer where 
a 5 mm margin was added. The brain stem, op-
tic chiasm, optic nerves, eyes and lenses were 
selected as the planning risk volume (PRV) in 
pituitary gland cases, and in tonsil cancer cases 
– the brain stem, parotid glands, spinal cord, 
oral cavity and larynx. In both cases additional 
structure surrounding the PTV for dose reduc-
tion in healthy tissues was used.
Preparation of treatment plans
6 MV photons were used for the Tomotherapy 
and the linear accelerator IMRT plan compu-
tations. Moreover, the same method of nor-
malization was used in both simulations. In 
the linear accelerator case the sliding window 
technique with the 120 millennium MLC was 
used. Doses and leaf motions were calculated 
by AAA and Beamlet algorithms respectively 
[22–25]. The 7-fi eld coplanar (for tonsil) and 
non-coplanar (for pituitary gland) techniques 
were used. Orientation of beams was selected 
individually for every patient by one
physicist. In this way, the tonsil cases in-
cluded an anterior (gantry rotation set at 0 de-
grees: GR = 0°), 2 anterior oblique (GR ranges 
from 30° to 50° and from 310° to 330°), 2 lateral 
oblique (GR ranges from 90° to 110° and from 
250° to 270°), and 2 posterior oblique beams 
(GR ranges from 140° to 155°
and from 2050 to 2200) and the pituitary 
gland cases – 2 lateral oblique (GR ranges 
from 80° to 100° and from 260°0 to 280°), an 
anterior (GR=0°) and 4 non-coplanar beams 
in cranial–caudal direction (table rotation was 
270° for each beam and GR ranges were: 330° – 
350° for fi rst, 20° – 40° for second, 60° – 80° for 
third, and 110° – 130° for fourth beam). More-
over, the optimal beam orientation from the 
presented ranges was selected using criteria 
of the best PTV coverage and PRV sparing.
The same patients (through Dicom trans-
fer) were planned at the Tomotherapy Hi-Art 
Inc. installation at St-Luc University Hospital 
in Brussels, Belgium. Beamlet and superposi-
tion convolution algorithms were used during 
Tomotherapy planning. Tomotherapy lasers 
were moved for each patient to the isocentre 
positions used in linear accelerator planning 
(Eclipse). Moreover, 1.0 cm fi eld width was used 
for dose computations except the PTV3 of tonsil 
cancer irradiated to 50 Gy where the width was 
2.5 cm. In both situations pitch and modulation 
factor were set respectively at 0.215 and 2.4.
System constraints, based on the physi-
cian’s intents, were chosen identically for 
Tomotherapy and accelerator based IMRT 
plans. The maximum, minimum and dose for 
selected percent of volume were used for each 
PRV and PTV. Weights (Eclipse TPS) or pri-
orities (Tomotherapy TPS) of constraints were 
changed individually for each patient in order 
to obtain the best results during optimization 
of the plans. For example, if for optic chiasm 
the maximum dose established by the physi-
cian was 54 Gy then constraints used in both 
methods and for all patients were: maximum 
dose – 50 Gy, and dose absorbed in 10% of the 
optic chiasm volume – 40 Gy. Table 1 shows 
the physician’s intents and constraints used 
for pituitary gland and tonsil cancer plans.
DVH analysis
DVH analysis was the fi rst method of dose dis-
tribution comparison between Tomotherapy 
and linear accelerator planning for pituitary 
gland and tonsil cancer. Mean DVHs with 
confi dence range performed at a=0.05 were 
computed for each structure and for two plan-
ning methods. In computations symmetrical 
PRVs such as lenses, eyes and optic nerves 
for pituitary gland cases were included as 
one structure. Parotids in tonsil cancer cases 
were grouped as high risk structures (close to 
PTV2) and low risk (far from PTV2). In Tomo-
therapy planning the direction blocked meth-
od for parotids in tonsil cases and for lenses in 
pituitary gland cases was used. Moreover, the 
obtained parameters for the dose distribution 
corresponding to the physician’s intents and to 
the system constraints were compared.
Two-component conformity index 
formula (TCCI). General overview
The second method of analysis was the two-
component conformity index formula (TCCI). 
The differences between the dose distribution 
for two planning methods were evaluated by 
the TCCI formula dependent on physician’s 
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intent and described coverage of the PTV and 
excess dose in healthy tissue components. 
Moreover, TCCI computations were discussed 
in the light of current CI formulas. The gen-
eral formula of the TCCI was expressed as:
);( ESCSTCCI             (1),
where CS is the coverage score describing 
quality of the PTV coverage by more than one 
isodose and ES is the excess score describing 
quality of the excess doses in healthy tissues 
by more than one isodose including PRV in-
fl uence. The number and value of isodoses in-
cluded in the TCCI formula are dependent on 
the physician’s specifi cation. Figure 1 shows a 
schematic view of the CS and ES components 
included in the TCCI formula.
Coverage Score component of the TCCI
The mathematical formula of the coverage 
score is dependent on three dose-volume re-
gions of analyzed isodoses specifi ed by a phy-
sician. For example, ICRU recommendations 
suggest four dose-volume dependence regions 
to verify dose distribution in PTV: 1/ 99% of 
PTV volume cannot absorb doses lower than 
90% of the prescribed dose; 2/ 95% of PTV 
volume – doses are higher than 95%; 3/ 50% 
of PTV volume – doses are equal to 100%, and 
4/ 1% of PTV volume – doses are lower than 
105%.
For the fi rst two regions, described as low 
doses absorbed in specifi ed high percent vol-
ume of PTV, coverage score was described as:
totPTV
nPTV
i V
V
CS
,
,    
        
(2),
where VPTV,n is the PTV volume covered by the 
specifi ed isodose, VPTV,tot is the total volume of 
the PTV and n is the number of specifi cations 
included in the physician’s intent – in this ex-
ample 1 and 2 specifi cations can be solved by 
this formula.
For regions including doses close to 100% of 
the prescription, CS is expressed as follows:
¸¸¹
·
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(3),
where VAC,n is the theoretical volume of the 
PTV specifi ed by the physician (AC – accep-
tance criteria) corresponding to the real vol-
ume of PTV covered by isodose highlighted 
in n – specifi cation (VPTV,n). In this example n 
corresponds to 3 specifi cations.
For regions of high doses absorbed in the 
specifi ed low percent of PTV volume, the CS 
formula is:
¸¸¹
·
¨¨©
§ 
totPTV
nPTV
i V
V
CS
,
,1   
             
(4),
In this example formula 4 could be used in 
the 4th ICRU specifi cation.
Finally, CS is a product of the CSn compo-
nents dependent on the acceptance criteria in-
cluded in the physician’s specifi cation and can 
be expressed mathematically as:

 
 
n
i
nCSCS
1
   
       
(5),
where CS is total coverage score ranging from 
0 to 1 (the best value) and n is the number of 
the acceptance criteria specifi ed by the physi-
cian.
Fig. 1. Schematic view of high dose regions a) covering part of 
PTV volume and b) received in healthy tissues
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Excess Score component of the TCCI
The impact of doses absorbed in healthy tis-
sues and the doses specifi ed by the physician 
for PRVs was described by a second compo-
nent of the TCCI formula called Excess Score 
(ES).
The ES component is dependent on accep-
tance criteria specifi ed in the physician’s in-
tent such as: 1/ the critical doses described as 
maximum or mean dose or the dose–volume 
parameter for PRVs (Table 1) and 2/ accept-
able excess index (EI) defi ned as volume of 
healthy tissues irradiated by specifi ed isodose 
normalized to the PTV volume. The EI formu-
la was expressed mathematically as follows:
totPTV
nPTVnBody
V
VV
EI
,
,,    
        
(6),
where VBody,n and VPTV,n are the volumes of body 
and PTV covered by n-specifi ed isodose level 
and VPTV,tot is the total volume of the PTV. In 
this study fi ve isodose levels (85%, 90%, 95%, 
100%, 105%) were used and the acceptable ex-
cess (AE) was 1.0, 0.5, 0.3, 0.1, 0.0 respectively 
for each isodose. For example, if 85% isodose 
level covered more than two volumes of PTV 
(EI > 1.0) then the criterion was not realized. 
In this situation the following formula was 
used for ES calculation:
n
nn
i EI
AEEI
ES
    
         
(7),
where EIn is the observed excess index for n-
selected isodose level and AEn is the acceptable 
value of excess index for n-selected isodose 
level specifi ed by the physician. In a different 
situation when EIn ≤ AEn excess score goes to 
0 (ESn = 0).
The second arm of the ES formula was used 
to verify the agreement between critical doses 
for PRVs included in intent and corresponding 
values obtained during plan preparation. Risk 
index (RIj) receives 0 and 1 values for each 
PRV. When RIj = 1 then for PRVj observed 
parameters were higher than acceptable. In 
Structure Physician’s Intent(1) System constraints(2)
Tumour of the pituitary gland
PTV ICRU(3) Dmin, Dmax, D(V50): 56 Gy
Brain stem Dmax < 54 Gy Dmax: 50 Gy; D(V30): 20 Gy
Chiasm Dmax < 54 Gy Dmax: 50 Gy; D(V10): 40 Gy
Optic nerves Dmax < 54 Gy Dmax: 40 Gy; D(V20): 20 Gy
Eyes Dmax < 25 Gy Dmax: 20 Gy; D(V5): 5 Gy
Lenses(4) Dmax < 7 Gy Dmax: 4 Gy; D(V50): 2 Gy
Tonsil cancer I phase (50 Gy) II phase (20 Gy)
PTV1 (to 50 Gy) ICRU
(3) Dmin, Dmax, D(V50): 50 Gy No
PTV2 (to 20 Gy) ICRU
(3) No Dmin, Dmax, D(V50): 20 Gy
Brain stem Dmax < 54 Gy Dmax: 40 Gy; D(V30): 15 Gy Dmax: 5 Gy; D(V30): 3 Gy
Spinal Cord Dmax < 45 Gy Dmax: 35 Gy; D(V50): 25 Gy Dmax: 8 Gy; D(V50): 6 Gy
Parotids(4) Dmean < 26 Gy Dmax: 40 Gy; D(V30): 15 Gy Dmax: 5 Gy; D(V30): 2 Gy
Oral cavity Dmean < 35 Gy Dmax: 45 Gy; D(V30): 30 Gy Dmax: 10 Gy; D(V30): 5 Gy
Larynx Dmean < 35 Gy Dmax: 45 Gy; D(V50): 20 Gy No
(1) Intents depended on the total prescribed dose: 56 Gy in pituitary gland and 70 Gy in tonsil cancer
(2) Only weights or priority constraints were changed
(3) ICRU recommendations: D(V99) ≥ 90 %, D(V95) ≥ 95 %, D(V50) ≥ 100 %, D(V1) ≤ 105 %
(4) Direction blocked method used in Tomotherapy planning
Table 1. Physician’s intent and system constraints for tumour of the pituitary gland. D(Vx) – dose absorbed in x-percent 
volume of PRV or PTV. Dmin – minimum dose, Dmax – maximum dose, Dmean – mean dose
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another way, when observed parameters were 
lower than acceptable, then risk index goes to 
0. For example, if acceptable mean dose for 
parotids specifi ed by the physician was Dmean 
Fig. 2. Mean dose-volume histograms of the planning target 
volumes received for fi ve patients with tumour of the pituitary 
gland. Red line presents DVH received for Tomotherapy and black 
presents Eclipse planning. Solid lines present mean DVHs and 
dashed present ranges of confi dence performed at a =0.05
≤26 Gy and observed mean dose was lower 
than acceptable, then risk index goes to 0.
Finally, excess score was expressed math-
ematically as follows:
¦¦
  
 
k
j
j
n
i
i RIESn
ES
11
1  
          
(8),
where n = number of isodose levels, ESi = 
excess score calculated for i-level of isodose, 
and RIj = risk index calculated for PRVj.
Excess score receives values from 0 (the 
best value) to
¦
 

n
i
iESn
k
1
1
where k is the number of PRVs included in 
calculations.
RESULTS
Figures 2 and 3 show the differences between 
doses in PTV delivered by Tomotherapy and 
linear accelerator (Eclipse) methods for tu-
mour of the pituitary gland and tonsil cancer. 
The red line presents DVH received for To-
motherapy and black presents Eclipse plan-
ning. Solid
lines present mean DVHs and dashed pres-
ent ranges of confi dence level performed at 
a=0.05.
The selected PRVs dose comparisons for 
Tomotherapy and Eclipse plans in pituitary 
gland and tonsil groups are shown in Figures 
4 and 5. Figure 4 shows brain stem, optic chi-
asm optic nerves and eyes dose-volume histo-
grams for Tomotherapy and Eclipse planning 
in tumour of the pituitary gland, and Figure 
5 shows spinal cord and high and low risk pa-
rotids in tonsil cancer. Similarly as in Figures 
2 and 3, the same methods of visualization 
(colours and lines) were used.
Table 2 shows results of the coverage score 
computations for PTVs of pituitary gland tu-
mour and CTV2 irradiated to 70 Gy of tonsil 
cancer cases. Highlighted rows (black colour) 
split the table into two groups. The fi rst col-
umn includes number (n) of criterion level 
included in CSi computations (formulas 2, 3, 
4) presented in corresponding rows. Criterion 
levels were defi ned as: 1/ for n=1 99% of PTV 
volume cannot absorb doses lower than 90% of 
prescribed dose (PD); 2/ for n=2 95% of PTV 
Fig. 3. Mean dose-volume histograms of the planning target 
volumes received for fi ve tonsil cancer patients. Red line presents 
DVH received for Tomotherapy and black presents Eclipse plan-
ning. Solid lines present mean DVHs and dashed present ranges 
of confi dence performed at a=0.05
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absorbed doses not lower than 95% of PD; 3/ 
for n=3 50% of PTV absorbed doses equal to 
or higher than PD (100%) and 4/ for n=4 1% 
of PTV absorbed doses lower than 105% of 
PD. Bolded rows show CS result (product of 
received CSi, formula 5) for each patient and 
groups of delivery method, respectively.
Table 3 shows results of excess score (ES) 
computations for PTVs delineated for tu-
mour of the pituitary gland and CTV2 of ton-
sil cancer. Table 3 like Table 2 was split into 
two groups. The fi rst column includes isod-
ose level (D [%]) used for excess index (EI) 
computations (formula 6) and number (n) of 
criterion level included during ESi computa-
tions (formula 7). EI and ESi are presented, 
corresponding to D[%] and n rows. Criterion 
levels were defi ned as: 1/ for n=1, EI is lower 
than 1 for volume enclosed by 85% isodose; 2/ 
for n=2, EI≤0.5 for 90% isodose; 3/ for n=3, 
EI≤0.3 for 95% isodose; 4/ for n=4, EI≤0.1 for 
100% isodose and 5/ for n=5, EI=0 for 105% 
Fig. 4. Selected planning risk volumes dose comparison for a) optic chiasm, b) brain stem, c) optic nerves and d) eyes. Each 
plot contains mean DVHs (solid lines) with corresponding confi dence range (dashed lines) for 5 pituitary gland cases. For 
a) and b) structures signifi cant dose difference regions were marked and enlarged. Red lines present histograms for Tomo-
therapy and black, Eclipse. a=0.05
Figure 4
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isodose. Bolded rows show ES result (for-
mula 8) for each patient and delivery method 
groups, respectively. Figures 6 and 7 show de-
pendence between absorbed doses and excess 
index (Table 3) obtained for Tomotherapy and 
Eclipse plans in pituitary gland and tonsil can-
cer respectively.
DISCUSSION
DVH analysis for PTVs and PRVs
General DVH analysis shows good coverage 
of PTVs for both Tomotherapy and Eclipse 
plans. However, statistically signifi cant dif-
ferences between the two delivery modalities 
were observed for PTV volumes enclosed with 
dose range from 98% to 102%. For pituitary 
gland cases, larger volume of PTV absorbed 
this range of doses as a result of Eclipse plan-
ning (p=0.01). The reverse situation was ob-
served in tonsil cancer cases – doses close to 
the prescribed dose were absorbed in a larger 
volume of PTV as a result of Tomotherapy 
Fig. 5. Selected planning risk volumes dose comparison for a) spinal cord, b) parotids low risk and c) parotids high risk. Each 
plot contains mean DVHs (solid lines) with corresponding confi dence range (dashed lines) for 5 tonsil cancer patients. For 
each presented structure signifi cant dose difference regions were marked and enlarged. Red lines present histograms for 
Tomotherapy and black, Eclipse. a =0.05
Figure 5
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planning (p=0.015). For example: 1/ in the 
pituitary gland group, Eclipse plans provide 
61% of PTV volume enclosed by the pre-
scribed dose, and Tomotherapy plans – 50% 
(Figure 2); 2/ in the tonsil group, Eclipse 
plans – 44%, and Tomotherapy – 55% (Figure 
3). Moreover, lower standard deviation for 
Tomotherapy than for Eclipse (0.7 Gy versus 
1.1 Gy in tumour of pituitary gland and 0.8 Gy 
versus 1.2 Gy in tonsil cancer) suggest better 
dose homogeneity for the fi rst method. Simi-
lar results were observed in other studies 
of Tomotherapy and linear accelerator plan 
comparisons [26, 27].
All plans successfully realized the intents 
specifi ed by the physician, related to accepted 
doses in PRVs. Although satisfactory dose spar-
ing in PRVs is realized by two compared mo-
dalities, for structures located close to the PTVs 
such as the optic chiasm or brain stem in pi-
tuitary gland cases with partially overlapping 
PTVs, and parotids in tonsil cases, better dose 
distributions for Tomotherapy plans were ob-
served. For example, in pituitary gland cases, 
the high dose region was signifi cantly better re-
duced through Tomotherapy plans in brain stem 
(p=0.02) and optic chiasm (p=0.013). High dose 
region for PRVs was defi ned as the range from 
Dmax – 75% of Dmax to Dmax. The maximum dose 
(Dmax) specifi ed by the physician was 54 Gy for 
both structures. As a result the high dose region 
included part of PRV volumes enclosed by doses 
from 40.5 Gy to 54 Gy (see Figures 4a – optic 
chasm, 4b – brain stem and enlarged regions). 
In tonsil cases, the middle dose region (near to 
the median dose) for parotids and spinal cord 
was better reduced through Tomotherapy than 
Eclipse plans. The p-values were 0.031 for low 
risk and 0.04 for high risk parotids, and 0.023 
for spinal cord. Middle dose regions were estab-
lished from 5 Gy to 20 Gy for parotids and from 
25 Gy to 43 Gy for spinal cord (see Figures 5a – 
spinal cord, 5b – low risk parotids and 5c – high 
risk parotids with enlarged regions). No signifi -
cant differences for other PRVs such as optic 
nerves, eyes and lenses for pituitary gland and 
oral cavity and larynx for tonsil cancer were ob-
served. Figures 4c and 4d show example DVHs 
for optic nerves and eyes in the pituitary gland 
group. Our results correspond to other works 
where dose reduction in PRVs was evaluated 
[28–30].
Fig. 6. Dependence between excess index and absorbed doses 
[%] for Tomotherapy (red colour) and Eclipse (black colour) in 
pituitary gland group. Solid lines present means and dashed 
confi dence range performed at a =0.05
Fig. 7. Dependence between excess index and absorbed doses 
[%] for Tomotherapy (red colour) and Eclipse (black colour) in 
tonsil cancer group. Solid lines present means and dashed confi -
dence range performed at a=0.05
TCCI analysis
Observed results of coverage score (Table 2) 
confi rmed good coverage of PTVs for both To-
motherapy and Eclipse plans (mean CS range 
from 0.936 to 1). However, some discrete differ-
ences, not detected during DVH analysis, were 
observed. In pituitary gland cases the worst re-
sults for criteria 1 and 2 (see Table 2 descrip-
tion), described as low dose distribution in PTV 
for Eclipse plans, were obtained. For example, 
for criterion 2 (95% of PTV cannot absorb dos-
es lower than 95% of the prescribed dose) in 
pituitary gland cases all patients received an 
ideal CSi value equal to 1 for Tomotherapy, and 
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for Eclipse, second, third and fourth patients 
received lower values of CSi – 0.948 , 0.943, 
0.947, respectively (Table 2).
Differences in PTV volumes enclosed with 
dose range from 98% to 102% observed during 
DVH analysis were plain described by TCCI 
analysis. Only a few statistically signifi cant 
differences were also clinically signifi cant be-
cause some of the observed differences dur-
ing DVH analysis were above clinical speci-
fi cation. For example, in the pituitary gland 
group lower mean volume of PTV received 
prescribed doses for Tomotherapy (50%) than 
for Eclipse plans (61%). This was not clinical-
ly signifi cant because 50% of PTV absorbing 
the prescribed dose was an acceptable value 
specifi ed by the physician. In analysis for in-
dividual patients, CSi values received for this 
criterion were close to 1 in Tomotherapy – 
0.992, 1.000, 0.997, 0.999, 1.000 for fi rst to fi fth 
patient respectively (Table 2). These results 
suggest that doses received by 50% of volume 
were near to the prescribed dose.
In tonsil cancer the opposite situation was 
observed. 55% of mean PTV volume absorbed 
the prescribed dose for Tomotherapy and 44% 
for Eclipse plans. In this situation statistically 
signifi cant differences were confi rmed clini-
cally. Doses absorbed by 50% of the PTV for 
Eclipse plans were signifi cantly lower than 
the prescribed dose. As a result each patient 
received a relatively small CSi value – 0.939, 
0.916, 0.932, 0.941, 0.952 respectively for the 
fi rst to fi fth patient (Table 2).
For each patient and both delivery methods, 
doses absorbed in PRVs were lower than doses 
specifi ed as acceptable criteria. In this situa-
tion the risk index component (RIj) included 
in excess score computations (formula 8) goes 
to 0. Only high doses received in healthy tis-
sues not specifi ed as PRVs affected fi nal ES 
values.
The region of normal tissues, enclosed by 
high doses, was defi ned using fi ve isodose 
levels: 85%, 90%, 95%, 100%, 105%. Accept-
able excess indices defi ned by the physician 
Table 2. Coverage Score (CS) computations for PTVs delineated for tumour of the pituitary gland and CTV2 of tonsil cancer. 
Highlighted rows (black colour) split table into two respective groups. The fi rst column includes number (n) of criterion level 
included in CSi computations (formulas 2, 3, 4) presented in corresponding rows. Criterion levels were defi ned as: 1/ for n=1 
99% of PTV volume cannot absorb doses lower than 90% of prescribed dose (PD); 2/ for n=2 95% of PTV absorbed doses 
not lower than 95% of PD; 3/ for n=3 50% of PTV absorbed doses equal to or higher than PD (100%) and 4/ for n=4 1% 
of PTV absorbed doses lower than 105% of PD. Bolded rows show CS result (product of received CSi, formula 5) for each 
patient and groups of delivery method, respectively
Patient: 1 2 3 4 5 1 2 3 4 5
n Tomotherapy planning (HiArt System) Linear accelerator planning (Eclipse)
tumor of the pituitary gland
1 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2 1.000 1.000 1.000 1.000 1.000 1.000 0.948 0.943 0.947 1.000
3 0.992 1.000 0.997 0.999 1.000 1.000 1.000 1.000 1.000 1.000
4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
CS: 0.992 1.000 0.997 0.999 1.000 1.000 0.948 0.943 0.947 1.000
Mean CS: 0.968 0.998 0.968
tonsil cancer PTV2 (to 70Gy)
1 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
3 1.000 1.000 1.000 1.000 1.000 0.939 0.916 0.932 0.941 0.952
4 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
CS: 1.000 1.000 1.000 1.000 1.000 0.939 0.916 0.932 0.941 0.952
Mean CS: 1.000 0.936
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Patient: 1 2 3 4 5 1 2 3 4 5
 Tomotherapy planning (HiArt System) Linear accelerator planning (Eclipse)
tumor of the pituitary gland
D [%]  Excess Index for Tomotherapy Excess Index for Eclipse
85 1.1 1.6 0.8 1.8 0.9 2.2 2.1 1.3 2.0 1.8
90 0.3 1.2 0.6 0.4 0.4 1.6 1.6 0.8 1.5 1.2
95 0.1 0.9 0.3 0.2 0.2 0.5 1.1 0.4 0.9 0.6
100 0.0 0.5 0.0 0.1 0.0 0.2 0.5 0.2 0.3 0.0
105 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
n Excess Scores Component for Tomotherapy Excess Scores Component for Eclipse
1 0.13 0.37 0.00 0.44 0.00 0.54 0.51 0.25 0.50 0.45
2 0.00 0.59 0.15 0.00 0.00 0.69 0.69 0.41 0.66 0.60
3 0.00 0.66 0.13 0.00 0.00 0.40 0.73 0.23 0.67 0.53
4 0.00 0.80 0.00 0.00 0.00 0.42 0.82 0.43 0.69 0.00
5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ES: 0.03 0.61 0.07 0.11 0.00 0.51 0.69 0.33 0.63 0.39
Mean ES: 0.16 0.51
tonsil cancer PTV2 (to 70Gy)
D [%]  Excess Index for Tomotherapy Excess Index for Eclipse
85 1.2 1.2 1.2 1.7 1.0 1.8 1.5 2.0 2.4 2.0
90 0.6 0.7 0.6 0.1 0.6 1.1 0.9 1.2 1.4 1.2
95 0.0 0.2 0.2 0.3 0.3 0.5 0.2 0.5 0.6 0.4
100 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.3 0.0 0.1
105 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
n Excess Scores Component for Tomotherapy Excess Scores Component for Eclipse
1 0.18 0.18 0.19 0.42 0.00 0.43 0.33 0.50 0.58 0.49
2 0.15 0.30 0.17 0.00 0.12 0.53 0.41 0.58 0.64 0.57
3 0.00 0.00 0.00 0.00 0.11 0.39 0.00 0.36 0.47 0.33
4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.68 0.00 0.00
5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ES: 0.08 0.12 0.09 0.10 0.07 0.34 0.19 0.53 0.42 0.35
Mean ES: 0.09 0.36
Table 3. Excess score (ES) computations for PTVs delineated for tumour of the pituitary gland and CTV2 of tonsil cancer. 
Highlighted rows (black colour) split table into two respective groups. First column includes isodose level (D [%]) used for 
excess index (EI) computations (formula 6) and number (n) of criterion level included during ESi computations (formulas 7). 
EI and ESi are presented, corresponding to D[%] and n rows respectively. Criterion levels were defi ned as: 1/ for n=1, EI is 
lower than 1 for volume enclosed by 85% isodose; 2/ for n=2, EI≤0.5 for 90% isodose; 3/ for n=3, EI≤0.3 for 95% isodose; 
4/ for n=4, EI≤0.1 for 100% isodose and 5/ for n=5, EI=0 for 105% isodose. Bolded rows show ES result (formula 8) for 
each patient and delivery method groups
for specifi ed isodoses were: 1/ 85% isodose 
could cover the volume of normal tissues cor-
responding to PTV volume (EI≤1); 2/ 90% 
isodose (EI≤0.5); 3/ 95% isodose (EI≤0.3); 4/ 
100% isodose (EI≤0.1) and 5/ doses higher 
than 105% could not cover normal tissues and 
can be absorbed only in PTV volume (EI=0). 
Lower excess scores for Tomotherapy plans 
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were observed for each comparison. The de-
pendence between absorbed doses and excess 
index obtained for Tomotherapy and Eclipse 
plans is graphically illustrated in Figures 6 
and 7. Moreover, decreasing dependence be-
tween excess score and volume of PTV was 
observed. For example, mean ES values were: 
0.16 for Tomotherapy and 0.51 for Eclipse 
plans in the pituitary gland group (mean PTV 
volume was 19.8 cm3) and 0.09 for Tomothera-
py and 0.36 for Eclipse plans in the tonsil can-
cer group (mean PTV volume was 107.1 cm3).
Detailed results obtained during the TCCI 
analysis were not possible in current CI for-
mulas where only one isodose level was used 
without dose in PRV evaluation. Including 
more than one isodose level for dose evalua-
tion in PTV and healthy tissues not specifi ed 
as PRVs and including impact of the dose ab-
sorbed in PRVs provides more precise con-
clusions during evaluation or comparison of 
plans. Moreover, splitting coverage and excess 
components allows clearer presentation of the 
results than in current CI formulas where one 
value describes two effects. Finally, the de-
pendence of the physician’s intents makes the 
TCCI formula a more elastic tool applied to 
clinical routine. The TCCI formula is experi-
mentally used as a second tool for verifi cation 
of plans prepared for patients routinely treated 
in the Greater Poland Cancer Centre. A spe-
cial computer program based on mathemati-
cal expression included in the TCCI formula 
was created. This program compiled TCCI 
results for all DVH data previously exported 
as ASCII fi les from the Eclipse Planning Sta-
tion. However, the usefulness of delivered in-
formation means that the TCCI could be used 
as a primary or alternative method of quick 
dose-volume verifi cation fi nally supported by 
advanced DVH analysis.
CONCLUSIONS
General DVH analysis shows similar coverage 
of PTV volume for Tomotherapy and Eclipse 
plans except for some statistically signifi cant 
differences for PTV volumes receiving doses 
close to the prescription dose (in the pituitary 
gland, Eclipse plans provide 61% of PTV vol-
ume enclosed by the prescribed dose, and To-
motherapy plans 50%; and in tonsil cancer, 
Eclipse plans – 44%, Tomotherapy – 55%). 
These differences were clinically confi rmed 
for tonsil cancer through TCCI analysis. More-
over, TCCI analysis shows better coverage of 
PTV volume through 90% and 95% isodose 
levels for Tomotherapy plans.
Clinically accepted dose sparing in PRVs 
for both plan preparation methods was pro-
duced. For Tomotherapy plans, better high 
dose region reduction for brain stem (p=0.02) 
and optic chiasm (p=0.013) in the pituitary 
gland and middle dose region reduction for 
parotids (high risk p=0.04, low risk p=0.031) 
and spinal cord (p=0.023) in tonsil cases was 
observed. Moreover, TCCI analysis shows bet-
ter dose reduction in healthy tissues not speci-
fi ed as PRVs. In the pituitary gland excess 
score was 0.16 for Tomotherapy and 0.51 for 
Eclipse plans. In tonsil cancer – 0.09 and 0.36 
for Tomotherapy and Eclipse IMRT plans re-
spectively.
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